Pre-earnings options volume in Crispr Therapeutics is 1.4x normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 4.4%, or $2.08, after results are released. Median move over the past eight quarters is 2.7%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Crispr Therapeutics options imply 4.9% move in share price post-earnings
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences
- Crispr Therapeutics price target lowered to $70 from $100 at JMP Securities
- CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference